Turn a daily habit into early disease risk detection
Flux is a smart toothbrush head that uses saliva-based biomarkers to flag early prediabetic risk before symptoms appear.
This is a research prototype under development. Not approved for clinical use. Information for evaluation purposes only.
Prediabetes is invisible until damage occurs
The barrier is not patient willingness—it is diagnostic friction.
Testing requires time, access, and disruption to daily life. Early detection depends on overcoming this friction.
Why current solutions fail
Blood tests
Episodic snapshots miss the continuous metabolic story
CGMs
Overkill for prevention—designed for diabetics, not early-stage users
Wearables
They react to metabolic dysfunction, but can't predict or prevent it
The problem with blood tests
Episodic snapshots miss the continuous metabolic story
None of these solutions integrate seamlessly into daily life without behavioral change or clinical access.
Daily habits drive the highest compliance.
No new routine to learn. No reminder needed. No compliance friction.
Flux enables preventative metabolic screening.
A seamless 5-step process that integrates into existing daily habits
Brush
Normal brushing routine
User brushes teeth as normal—no change to daily habit required. The toothbrush functions identically to a standard electric brush.
Saliva contact
Passive sample collection
Saliva naturally contacts embedded biosensors during brushing. No additional steps, swabs, or conscious effort needed.
Biosensor capture
Biomarker detection
Sensors detect metabolic biomarkers (glucose, ketones, lactate) in real-time from saliva. Proprietary sensor array provides instant readings.
Secure analysis
Encrypted processing
Data is encrypted and analyzed using proprietary algorithms. HIPAA-compliant transmission to secure cloud infrastructure.
App insight
Risk trend visibility
Trends displayed in mobile app—actionable insights without diagnosis. Historical tracking shows trajectory over weeks/months.
Flux flags early risk signals and trends. It does not diagnose disease.
Technology overview
Proprietary biosensing architecture designed for metabolic screening at the point of care.
Non-invasive collection during routine brushing
What makes Flux different
Detection before damage
Captures metabolic signals while reversible, not after symptoms appear
Zero friction adoption
Integrates into existing habits—no appointments, reminders, or routine changes
Context-aware intelligence
Continuous insights tied to behavior patterns, not discrete one-time measurements
Current progress
De-risked through lab validation. Hardware and software architectures defined.
Completed
- Functional biosensor prototype
- Saliva biomarker feasibility demonstrated in lab context
- CAD-complete hardware design
- App wireframes and secure data pipeline defined
Future milestones
- Clinical pilot validation
- Manufacturing partner selection
- Regulatory pathway submission
Target users
Primary Target
At-risk, undiagnosed prediabetics aged 15–40
Individuals with elevated risk factors who are not yet symptomatic or diagnosed. This population represents the highest-impact intervention window for prevention.
Secondary Target
Institutional pilots, insurers, community health programs
Organizations with strong incentives to identify at-risk populations early and demonstrate cost-effective preventative interventions.
Key insight: End user is not always the payer. Distribution and purchasing decisions often occur at the institutional level, creating dual go-to-market pathways.
Business model
Multi-layered revenue model combining hardware sales, consumables, and subscription insights
Hardware Entry
Low-cost smart toothbrush
Recurring Revenue
Replacement sensor heads
Subscription
Longitudinal insights & trends
B2B Partnerships
Distribution & institutional sales
Revenue model design: Low barrier to entry drives adoption, consumables create recurring touchpoints, and software subscriptions capture lifetime value through longitudinal health insights.
Team
Cross-functional expertise in biosensing, hardware, and clinical validation.
Dr. Sarah Chen
CEO
Biomedical engineering. Biosensor development.
Marcus Thompson
CTO
Embedded systems. Consumer hardware.
Dr. Aisha Patel
Chief Science Officer
Metabolic biomarkers. Clinical research.
James Liu
Head of Product
Digital health products. Regulatory strategy.
Current ask
We're seeking partners to validate and scale preventative diagnostics.
Pilot partners
Healthcare organizations interested in early-stage validation.
Research collaborators
Academic institutions with relevant biomarker expertise.
Diagnostic or regulatory advisors
Experts in wellness device classification and pathways.
Help validate preventative diagnostics
Partner with us to bring continuous metabolic screening to primary care.
© 2026 Flux Health Technologies. All rights reserved.